Research programme: CRE-decoy aptamers - Genta
Alternative Names: Research programme: decoy aptamers - GentaLatest Information Update: 09 Mar 2015
Price :
$50 *
At a glance
- Originator National Institutes of Health (USA)
- Class
- Mechanism of Action Genetic transcription modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer